GlassScriptPhysician profile
Jordan Terrell
NPI 1386221190
$1,343.30
in general payments reported to CMS, 2019-2025
22 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.61 · 2024: $258 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.47 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $262.85 | 2024-2025 | |
| Daiichi Sankyo INC. | $149.20 | 2024-2025 | Injectafer |
| Astellas Pharma US INC | $92.05 | 2025 | Veozah |
| Lilly USA, LLC | $64.65 | 2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $59.71 | 2024-2025 | |
| Novo Nordisk INC | $49.62 | 2025 | Wegovy, Ozempic |
| Insulet Corporation | $41.31 | 2025 | Omnipod |
| Vanda Pharmaceuticals INC. | $38.99 | 2024 | Hetlioz, Fanapt |
| Vertex Pharmaceuticals Incorporated | $36.04 | 2024-2025 | |
| Axsome Therapeutics, INC. | $34.49 | 2025 | Auvelity |
| Organon LLC | $31.67 | 2022-2025 | Nexplanon |
| Amgen INC. | $29.27 | 2025 | Repatha, Otezla |
| Ardelyx, INC. | $26.74 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.32 | 2025 | Accolade Sr |
| Eisai INC. | $22.24 | 2024 | |
| Esperion Therapeutics, INC. | $17.53 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.04 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $15.36 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.82 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $10.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Terrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.